β,β-Dimethylacrylshikonin
Based on 1 publication(s) in Google Scholar
β,β-Dimethylacrylshikonin (Isoarnebin I) is a naphthoquinone derivative that can be isolated from Lithospermum erythrorhizon Sieb. et Zucc. β,β-Dimethylacrylshikonin promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway. β,β-Dimethylacrylshikonin inhibits Notch-1 activation. β,β-Dimethylacrylshikonin inhibtis tumor cell proliferation, induces tumor cell apoptosis, and inhibits tumor growth.
For research use only. We do not sell to patients.
- Purity : 99.30%
- CAS No.: 24502-79-2
- Formula: C21H22O6
- Molecular Weight:370.40
-
Storage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) β,β-Dimethylacrylshikonin
More
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| B16-F0 | IC50 |
1.2 μM
Compound: DMAS
|
Cytotoxicity against mouse B16F0 cells assessed as reduction in cell viability after 24 hrs by MTT assay
Cytotoxicity against mouse B16F0 cells assessed as reduction in cell viability after 24 hrs by MTT assay
|
[PMID: 31961147] |
| B16-F0 | IC50 |
1.2 μM
Compound: DMAS
|
Cytotoxicity against mouse B16F0 cells assessed as reduction in cell viability after 48 hrs by MTT assay
Cytotoxicity against mouse B16F0 cells assessed as reduction in cell viability after 48 hrs by MTT assay
|
[PMID: 31961147] |
| CCRF-CEM | IC50 |
1.9 μM
Compound: 3
|
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
Cytotoxicity against human CCRF-CEM cells after 72 hrs by XTT assay
|
[PMID: 22530779] |
| HCT-116 | IC50 |
20 μM
Compound: 3
|
Cytotoxicity against human HCT116 cells after 72 hrs by XTT assay
Cytotoxicity against human HCT116 cells after 72 hrs by XTT assay
|
[PMID: 22530779] |
| HeLa | IC50 |
77 μM
Compound: 21
|
Inhibitory activity against DNA topoisomerase-1 obtained from Hela cells
Inhibitory activity against DNA topoisomerase-1 obtained from Hela cells
|
[PMID: 7699697] |
| MDA-MB-231 | IC50 |
23.2 μM
Compound: 3
|
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by XTT assay
Cytotoxicity against human MDA-MB-231 cells after 72 hrs by XTT assay
|
[PMID: 22530779] |
| MRC5 | IC50 |
2.4 μM
Compound: 3
|
Cytotoxicity against human MRC5 cells after 72 hrs by XTT assay
Cytotoxicity against human MRC5 cells after 72 hrs by XTT assay
|
[PMID: 22530779] |
| MRC5 | IC50 |
9.5 μM
Compound: DMAS
|
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human MRC5 cells assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| MUGMel1 | IC50 |
1 μM
Compound: DMAS
|
Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| MUGMel1 | IC50 |
1.1 μM
Compound: DMAS
|
Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| MUGMel1 | IC50 |
1.9 μM
Compound: DMAS
|
Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human MUGMel1 cells assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| MUGMel2 | IC50 |
1.7 μM
Compound: DMAS
|
Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| MUGMel2 | IC50 |
2.3 μM
Compound: DMAS
|
Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| MUGMel2 | IC50 |
5.1 μM
Compound: DMAS
|
Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human MUGMel2 cells harboring NRAS pQ61K mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| MUGMel2 | IC50 |
7.2 μM
Compound: 1-76
|
Antitumor activity against human MUG-Mel2 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
Antitumor activity against human MUG-Mel2 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
|
[PMID: 35367708] |
| SBcl2 | IC50 |
1.1 μM
Compound: 1-76
|
Antitumor activity against human SBcl2 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
Antitumor activity against human SBcl2 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
|
[PMID: 35367708] |
| SBcl2 | IC50 |
1.1 μM
Compound: 3
|
Cytotoxicity against human SBcl2 cells after 72 hrs by XTT assay
Cytotoxicity against human SBcl2 cells after 72 hrs by XTT assay
|
[PMID: 22530779] |
| SBcl2 | IC50 |
1.1 μM
Compound: DMAS
|
Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| SBcl2 | IC50 |
1.2 μM
Compound: DMAS
|
Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| SBcl2 | IC50 |
1.9 μM
Compound: DMAS
|
Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human SBcl2 cells harboring NRAS Q61I mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| U-251 | IC50 |
30.8 μM
Compound: 3
|
Cytotoxicity against human U251 cells after 72 hrs by XTT assay
Cytotoxicity against human U251 cells after 72 hrs by XTT assay
|
[PMID: 22530779] |
| WM164 | IC50 |
2.4 μM
Compound: DMAS
|
Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| WM164 | IC50 |
3 μM
Compound: DMAS
|
Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| WM164 | IC50 |
3.8 μM
Compound: DMAS
|
Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human WM164 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| WM164 | IC50 |
8.3 μM
Compound: 1-76
|
Antitumor activity against human WM164 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
Antitumor activity against human WM164 cells assessed as reduction in cell viability incubated for 72 hrs by XTT assay
|
[PMID: 35367708] |
| WM164 | IC50 |
8.3 μM
Compound: 3
|
Cytotoxicity against human WM164 cells after 72 hrs by XTT assay
Cytotoxicity against human WM164 cells after 72 hrs by XTT assay
|
[PMID: 22530779] |
| WM793 | IC50 |
0.7 μM
Compound: DMAS
|
Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 72 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| WM793 | IC50 |
0.8 μM
Compound: DMAS
|
Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 48 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
| WM793 | IC50 |
1.2 μM
Compound: DMAS
|
Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method
Cytotoxicity against human WM793 cells harboring BRAF V600E mutant assessed as reduction in cell viability after 24 hrs by EZ4U reagent based spectrophotometric method
|
[PMID: 31961147] |
In Vitro
β,β-Dimethylacrylshikonin (0-80 μM, 24 or 48 h) inhibits the G2/M phase transition and suppresses TNBC cell proliferation[3].
β,β-Dimethylacrylshikonin (0-10 μM, 24 h) induces mitochondrial-dependent apoptosis and reduces TNBC cell migration by antagonizing epithelial-mesenchymal transition[3].
β,β-Dimethylacrylshikonin (0-30 μg/mL, 48 h) reduces Notch-1 activation, expression of Jagged-1 and its downstream target Hes-1 in SGC-7901 cells[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:TNBC cells: MDA-MB-231, BT-549, HS578T cells
-
Concentration:2.5, 5, 10 μM
-
Incubation Time:24 h
-
Result:Increased the proportion of late apoptotic and necrotic cells.
Downregulated Bcl2, and increased Bax expression.
Increased the level of cleaved-caspase3.
In Vivo
β,β-Dimethylacrylshikonin (1 or 2 mg/kg, i.p., on alternate days) suppresses tumor growth in BT-549 xenograft mice model by inhibiting STAT3 phosphorylation[3].
β,β-Dimethylacrylshikonin (0.5-1.5 mg/kg, i.p.) suppresses tumor growth in MFC gastric xenograft mice model[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hydrocortisone induced impaired wound healing in cutaneous punch wound rat model[1]
-
Dosage:0.1% suspension in PBS; Hydrocortisone (30 mg/kg, i.m., daily, 11d)
-
Administration:applied topically on wounds, daily for 11 days
-
Result:HE staining: Showed more number of cells and vessels in the granulation tissue, and enhanced epidermal regeneration and collagen synthesis.
Enhanced the formation and migration of the epidermis over the wound.
Increased gap closure during normal and impaired healing
-
Animal Model:Athymic BALB/c nu/nu female mice (6- 8 week-old, 18-22 g), BT-549 cells were injected subcutaneously into the right thigh root of mice[3].
-
Dosage:1 or 2 mg/kg
-
Administration:i.p., on alternate days
-
Result:Decreased the expression of Ki67, CyclinB1 and CDK1 in tumor.
Up-regulated Bax expression and down-regulated Bcl-2 expression.
Increased the expression of E-cadherin and decreased N-cadherin and vimentin.
Decreased the level of p-STAT3 without changing total STAT3 levels.
Chemical Information
-
CAS No. 24502-79-2
-
Appearance Solid
-
Molecular Weight 370.40
-
Formula C21H22O6
-
Color Brown to reddish brown
-
SMILES
O=C1C2=C(O)C=CC(O)=C2C(C=C1[C@@H](C/C=C(C)/C)OC(/C=C(C)/C)=O)=O
-
Synonyms
Isoarnebin I
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
In Vitro:
DMSO : 12.5 mg/mL (33.75 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1.25 mg/mL (3.37 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 1.25 mg/mL (3.37 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1.25 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (12.5 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Human pluripotent stem cell endothelial-cell differentiation
Human pluripotent stem cell endothelial differentiation is based on stepwise developmental patterning: early activation of WNT/GSK3β inhibition promotes mesodermal or vascular progenitor entry, followed by endothelial specification using VEGF-related signaling, BMP4, FGF2, Notch modulation, or cAMP depending on the published protocol. Endothelial differentiation is read out by acquisition of CD31, CD34, VE-cadherin/CD144, KDR/VEGFR2, vWF, Tie2, NOS3, acetylated LDL uptake, tube/network formation, barrier function, and in vivo vessel-forming capacity where tested.
-
Somatic Cell Culture
A method of simulating the in vivo environment in vitro to maintain the cell growth, differentation and main functions.
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Endothelial Tube Formation Assay
Endothelial tube formation assay evaluates the ability of endothelial cells to attach, migrate, align, and organize into capillary-like networks when cultured on gelled basement membrane extract or Matrigel; the readout is the morphology and quantity of tube-like networks, which reflects an in vitro endothelial morphogenesis step related to angiogenesis. Basement membrane extract/Matrigel provides laminin-rich extracellular matrix cues that support endothelial differentiation into capillary-like structures, but it can contain biologically active growth factors, so growth-factor-reduced matrix is preferred when testing defined angiogenic stimulators or inhibitors.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Notch Pathway Solutions
The Notch pathway is a contact-dependent signaling pathway that controls cell-fate decisions, differentiation, proliferation, and tissue patterning through interactions between membrane-bound Notch receptors and membrane-bound ligands on neighboring cells. Canonical Notch signaling is activated when ligand engagement triggers proteolytic release of the Notch intracellular domain, which enters the nucleus and regulates transcription together with DNA-binding transcriptional complexes. In the canonical mechanism, ligand-dependent Notch activation leads to release of the intracellular Notch domain, and presenilin-dependent γ-secretase activity is required for production of the active intracellular signaling fragment. The released intracellular domain functions as a nuclear signal that converts Notch receptor activation at the membrane into transcriptional regulation of target programs such as HES/HEY-family genes and other context-dependent downstream targets. The literature links Notch p
-
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
-
Endothelial Cell Migration/Angiogenic Sprouting Assay
Endothelial cell migration and angiogenic sprouting assays are in vitro (and partially ex vivo-adapted) functional models that quantify the ability of endothelial cells to undergo coordinated migration, extracellular matrix invasion, and multicellular organization into capillary-like sprouts in response to pro-angiogenic stimuli such as VEGF, bFGF, or conditioned microenvironments. These assays are used to model early angiogenic events including tip-cell formation, directional migration, and lumen-like sprout extension, which collectively reflect angiogenic activation and vascular morphogenesis processes observed in vivo.
-
Vascular/Branching Fractal Analysis
Vascular/branching fractal analysis quantifies the geometric complexity of vessel trees or vascular networks from segmented 2D images, commonly by converting vessels into binary and/or skeletonized maps and estimating fractal dimension using box-counting or related approaches. Fractal dimension is interpreted as an image-derived readout of vascular branching complexity, space filling, or density, and has been applied to retinal photographs, fluorescein angiography, OCT angiography, capillary perfusion maps, and in vitro Matrigel angiogenesis networks. The assay readout is generated from vessel-positive pixels after image preprocessing, vessel segmentation, binarization, and optional skeletonization; reported outputs include fractal dimension, vessel density, branchpoint density, endpoint density, vessel length density, tortuosity, and generation-based branching metrics when VESGEN-style analysis is used. The biological interpretation is limited to quantitative vascular patterning and s
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
BrdU Incorporation Assay
Bromodeoxyuridine (BrdU) incorporation assay is based on the principle that BrdU, a thymidine analog, is incorporated into newly synthesized DNA during the S phase of the cell cycle, thereby serving as a marker of DNA replication and cellular proliferation. Incorporated BrdU can be detected using anti-BrdU antibodies following DNA denaturation, enabling visualization or quantification of proliferating cells through immunochemical detection methods such as immunofluorescence or immunohistochemistry.
-
CFSE Dye Dilution Proliferation Assay
The CFSE (carboxyfluorescein diacetate succinimidyl ester) dye dilution proliferation assay is based on the covalent labeling of intracellular proteins by a cell-permeant fluorescent dye that becomes fluorescent upon intracellular ester cleavage and then is stably retained within cells. As labeled cells divide, the dye is partitioned equally between daughter cells, resulting in a stepwise halving of fluorescence intensity that can be quantified by flow cytometry to determine the number of cell divisions undergone by each cell population. This fluorescence dilution approach enables quantitative tracking of lymphocyte proliferation at the single-cell level over multiple rounds of division. CFSE-based proliferation analysis has been widely applied to measure antigen-driven lymphocyte expansion in vitro, where discrete fluorescence peaks correspond to successive cell divisions and allow reconstruction of proliferative history within heterogeneous populations.
-
Dye-dilution cell tracking and proliferation staining
Dye-dilution cell tracking assays quantify cell proliferation by covalently labeling intracellular proteins with a stable fluorescent dye that is equally partitioned between daughter cells during mitosis, resulting in stepwise halving of fluorescence intensity with each cell division as measured by flow cytometry histograms. Carboxyfluorescein diacetate succinimidyl ester (CFSE) is a prototypical dye that diffuses into cells, is enzymatically converted into a fluorescent compound, and then covalently binds intracellular amine groups, producing long-lived fluorescence suitable for tracking multiple rounds of division in vitro and in vivo. Successive generations of dividing cells form discrete peaks of decreasing fluorescence intensity, enabling estimation of proliferation history, precursor frequency, and division index within heterogeneous populations. Alternative dyes such as CellTrace Violet (CTV) and far-red membrane dyes (e. g. , PKH26) follow the same dilution principle but differ
-
Patient-Derived Orthotopic Xenograft (PDOX)
Patient-derived orthotopic xenograft (PDOX) modeling implants fresh patient tumor tissue or patient-derived tumor cells into the anatomically corresponding organ or tissue site of immunodeficient mice, usually by surgical orthotopic implantation, to preserve patient tumor histology, local microenvironmental context, invasion, metastatic behavior, and treatment-response features better than subcutaneous implantation. PDOX readouts include tumor engraftment, orthotopic tumor growth, local invasion, metastasis, recurrence after resection, histologic similarity to the donor tumor, biomarker retention, molecular concordance, survival, and response or resistance to therapy. PDOX models are used for preclinical drug testing and individualized therapy evaluation, but engraftment success varies by tumor type and specimen quality.
-
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell Counting-Based Growth Curve Assay
Cell counting-based growth curve assays quantify cell proliferation by directly measuring changes in viable cell number over time using manual or automated counting methods such as hemocytometer-based counting or instrument-assisted cell enumeration, enabling construction of growth curves that reflect population expansion dynamics in response to culture conditions. A widely used approach is trypan blue exclusion with hemocytometer counting, where membrane-compromised (non-viable) cells take up the dye, allowing discrimination between viable and non-viable cells while simultaneously enabling total cell number quantification. Repeated sampling across time points allows estimation of proliferation rate, growth phases, and comparative growth kinetics between experimental conditions.
-
Colony Formation (Clonogenic) Assay
The clonogenic (colony formation) assay measures the ability of a single cell to retain reproductive viability and form a macroscopic colony, typically defined as a cluster derived from one progenitor cell after a defined growth period. This assay is widely used to evaluate cell survival after exposure to ionizing radiation or cytotoxic treatments and is considered a standard method in radiation biology for generating dose-response relationships of reproductive cell death. Colony formation reflects long-term proliferative capacity rather than short-term metabolic activity, and survival is quantified by comparing treated versus untreated conditions based on colony number and derived survival fractions.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
-
EdU Incorporation Assay (Click Chemistry-Based DNA Synthesis Measurement)
The EdU incorporation assay measures DNA synthesis by adding the thymidine analog 5-ethynyl-2′-deoxyuridine to cells or tissues, where it is incorporated into newly synthesized DNA during S phase. Incorporated EdU is detected by copper-catalyzed azide-alkyne cycloaddition, in which a fluorescent azide covalently reacts with the ethynyl group on EdU, allowing S-phase cells to be detected by fluorescence microscopy, flow cytometry, or high-content imaging. EdU detection does not require DNA denaturation or anti-BrdU antibody access, which preserves sample structure and improves compatibility with immunostaining and multiparameter cytometry compared with BrdU-based detection. EdU can be cytotoxic in a cell-type- and exposure-dependent manner, so pulse duration, concentration, and continuous-labeling designs should be validated for each cell type.
-
Ki-67 Immunostaining Proliferation Assay
Ki-67 immunostaining measures the growth fraction of a cell population by detecting Ki-67, a nuclear antigen present in proliferating cells and absent in quiescent G0 cells. The readout is the percentage of Ki-67-positive nuclei among total counted cells, commonly called the Ki-67 labeling index or proliferation index.
-
PCNA Immunodetection Proliferation Assay
PCNA immunodetection measures proliferative activity by detecting proliferating cell nuclear antigen, a nuclear protein associated with DNA polymerase δ function and DNA replication. The assay readout is the proportion of PCNA-positive nuclei among total counted cells, but PCNA labeling is not identical to BrdU labeling because PCNA can mark late G1/early S-associated replication competence and may persist beyond active DNA synthesis depending on fixation and extraction conditions.
-
Protocol for Cell Counting and Cell Density Analysis
Cell counting and cell-density analysis estimate the number of cells in a known volume or field area. Manual hemocytometer counting uses a chamber of defined geometry to convert counted cells into cells/mL, while automated counters and image-analysis workflows detect cell objects from optical, brightfield, fluorescence, impedance, or digital-image features. Trypan blue viability counting is based on dye exclusion: viable cells with intact membranes exclude dye, while non-viable cells with compromised membranes stain blue. The readout is total cell density, viable-cell density, dead-cell density, and percent viability. Cell density can also be estimated from microscopy images by counting objects per image area, from flow cytometry using calibrated volume or reference particles, or from in situ microscopy in bioreactors after calibration against reference methods such as hemocytometer or flow cytometry.
-
Patient-Derived Xenograft (PDX)
Patient-derived xenograft (PDX) models are generated by engrafting primary human tumor tissue directly into immunodeficient mice, allowing in vivo propagation of patient tumor biology without initial in vitro adaptation. These models are used to preserve key histopathological and molecular characteristics of the original tumor and enable assessment of tumor growth dynamics and therapeutic response in a living organism. The biological readout is tumor engraftment and subsequent growth in the murine host, which reflects the ability of human tumor cells to survive, vascularize, and expand in an immunocompromised microenvironment.
-
Subcutaneous Cell-Line-Derived Xenograft
Subcutaneous cell-line-derived xenograft (CDX) models are established by implanting cultured human cancer cell lines into immunodeficient mice, where the injected cells form localized tumors that can be monitored in vivo as a measure of tumorigenic potential, growth kinetics, and treatment response. These models are widely used in oncology research because they allow reproducible tumor formation and enable comparative assessment of tumor growth between different cell lines or genetic manipulations in a controlled in vivo microenvironment. Subcutaneous implantation of cancer cells in immunodeficient mice is a standard approach for evaluating tumor growth behavior and therapeutic response across multiple cancer types, including prostate, esophageal, pancreatic, and colon cancer models.
-
Orthotopic Cell-Line Xenograft
Orthotopic cell-line xenograft models involve implantation of human cancer cell lines into the anatomically corresponding organ of immunodeficient mice to reproduce tumor growth within a native microenvironment, enabling more clinically relevant tumor behavior compared with subcutaneous models. These models are widely used because orthotopic placement better recapitulates tumor progression, including invasion and metastatic spread, which are often underrepresented in heterotopic implantation systems. Compared with conventional xenografts, orthotopic implantation is described as more technically complex but provides improved simulation of tumor-microenvironment interactions and metastatic behavior, making it particularly valuable for translational oncology research. Surgical orthotopic implantation approaches have been emphasized as enabling faithful reproduction of clinical cancer features, including metastasis and disease progression patterns that align with the tumor’s organ of origi
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (702 KB)
- English - EN (702 KB)
- Français - FR (702 KB)
- Deutsch - DE (702 KB)
- Norwegian - NO (702 KB)
- Español - ES (702 KB)
- Swedish - SV (702 KB)
- Italian - IT (702 KB)
- Korean - KR (702 KB)
- Portuguese - PT (702 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zeng Z, et al. Arnebin-1 promotes angiogenesis by inducing eNOS, VEGF and HIF-1α expression through the PI3K-dependent pathway. Int J Mol Med. 2015 Sep;36(3):685-97. [Content Brief]
[2]. Sidhu GS, et al. Arnebin-1 accelerates normal and hydrocortisone-induced impaired wound healing. J Invest Dermatol. 1999 Nov;113(5):773-81. [Content Brief]
[3]. Wu Z, et al. β, β-Dimethylacrylshikonin potentiates paclitaxel activity, suppresses immune evasion and triple negative breast cancer progression via STAT3Y705 phosphorylation inhibition based on network pharmacology and transcriptomics analysis. Phytomedicine. 2023 Jun;114:154769. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.6998 mL | 13.4989 mL | 26.9978 mL | 67.4946 mL |
| 5 mM | 0.5400 mL | 2.6998 mL | 5.3996 mL | 13.4989 mL | |
| 10 mM | 0.2700 mL | 1.3499 mL | 2.6998 mL | 6.7495 mL | |
| 15 mM | 0.1800 mL | 0.8999 mL | 1.7999 mL | 4.4996 mL | |
| 20 mM | 0.1350 mL | 0.6749 mL | 1.3499 mL | 3.3747 mL | |
| 25 mM | 0.1080 mL | 0.5400 mL | 1.0799 mL | 2.6998 mL | |
| 30 mM | 0.0900 mL | 0.4500 mL | 0.8999 mL | 2.2498 mL |